https://www.selleckchem.com/pr....oducts/ldc195943-imt
pecific toxicity endpoint, warranting validation in independent cohorts and functional studies to elucidate biologic mechanisms. A subset of patients with oligometastatic cancer experience early widespread cancer dissemination and do not benefit from metastasis-directed therapy such as SABR. This study aimed to identify factors associated with early polymetastatic relapse (PMR). The SABR-5 trial was a single arm phase 2 study conducted at all 6 regional cancer centers across British Columbia (BC), Canada. SABR for oligometastases
Like
Comment
Share
